(+)-JQ1

For research use only.

Catalog No.S7110

245 publications

(+)-JQ1 Chemical Structure

CAS No. 1268524-70-4

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy.

Size Price Stock Quantity  
EUR 265 In stock
EUR 560 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's (+)-JQ1 has been cited by 245 publications

Purity & Quality Control

Choose Selective Target Protein Ligand Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)		 BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  Ml72R4VtdCCYaXHibYxqfHliQYPzZZk> NI\W[2ozPTBxNUCwM|ExODBibl2= NVn4fJVoOjRxNEivO|IhcA>? NUHqV|E2TE2VTx?= MUfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NFnrRpkzPjdyN{i4NS=>
BCPAP MlTTR4VtdCCYaXHibYxqfHliQYPzZZk> NImyO|EzPTBxNUCwM|ExODBibl2= NXLHVmg3OjRxNEivO|IhcA>? MWDEUXNQ M1PRe4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MkHaNlY4ODd6OEG=
K1  MXrD[YxtKEO7Y3zlJGF{e2G7 MVeyOVAwPTByL{GwNFAhdk1? NF;DWI84OiCq NEXYfJhFVVOR NGryc3ZienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS|EheGijc3W= MWKyOlcxPzh6MR?=
BCPAP MX3D[YxtKEO7Y3zlJGF{e2G7 M3zMcVI2OC93MECvNVAxOCCwTR?= M{TqUFczKGh? NIrlR3FFVVOR NYeyelRN[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl NFL2OpAzPjdyN{i4NS=>
Hep3B MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\4NE0yOCEQvF2= NFzBeWs2KGR? MYHEUXNQ NVL4UYpvUUN3ME2wMlA5KM7:TR?= NIHPRoQzPjV5NUG2Oy=>
HCCLM3 M3fBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInyOpYxNTFyIN88US=> NW[wWIdtPSCm MYLEUXNQ NG\TT5hKSzVyPUCuNVQh|ryP MXuyOlU4PTF4Nx?=
HuH7 M2TRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILFXZQxNTFyIN88US=> MlrtOUBl NYHHVnJLTE2VTx?= M1HMUmlEPTB;MD6yNUDPxE1? NHjycVkzPjV5NUG2Oy=>
HepG2 NGDHcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjMNE0yOCEQvF2= NEPjS|A2KGR? MUPEUXNQ NUTVfXV5UUN3ME2wMlM1KM7:TR?= M3jvVlI3PTd3MU[3
SMMC7721 NYLu[o94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGwNE0yOCEQvF2= M1zId|Uh\A>? M3f6e2ROW09? NUT0b3l7UUN3ME2wMlQyKM7:TR?= NXnzR4RZOjZ3N{WxOlc>
BEL7402 NXzkNWtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWewMVExKM7:TR?= MkLIOUBl M132cWROW09? NG\LWG9KSzVyPUCuOFch|ryP M2rV[|I3PTd3MU[3
MHCC97H M1G2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOwMVExKM7:TR?= NEnMSWs2KGR? MkH2SG1UVw>? M1\2[mlEPTB;MD60NUDPxE1? M36x[|I3PTd3MU[3
Hep3B M2TmOGNmdGxiQ4njcIUhSXO|YYm= NYDwUWF[OC5zL{CuOU8zNjVizszN NEnIWJM1QCCq MUjEUXNQ MojTcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh MoDoNlY2PzVzNke=
HCCLM3 NHnLOllE\WyuIFP5Z4xmKEG|c3H5 Ml3WNE4yNzBwNT:yMlUh|ryP MVS0PEBp NVrKWXVoTE2VTx?= NXP4Z|VXdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy|IHnuJJN2[i2JMTDwbIF{\cLi M4PkV|I3PTd3MU[3
Hep3B M3XSbWFxd3C2b4Ppd{BCe3OjeR?= MVmwMlEwOC53L{KuOUDPxE1? MnLLOFghcA>? MoXsSG1UVw>? MkXKZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? NEPDVGkzPjV5NUG2Oy=>
HCCLM3 NVrJSoNrSXCxcITvd4l{KEG|c3H5 MXywMlEwOC53L{KuOUDPxE1? NVTjNGhUPDhiaB?= MVfEUXNQ NV\kdmxp[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bTDmdo9uKG2rdH;jbI9v\HKrYR?= NITUeYUzPjV5NUG2Oy=>
A549 NEXIZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPUZoExNjFvMUCg{txO NU\CWWhQPzJiaB?= MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGfvbnMzPjRzNUKyOS=>
H157 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;aR5UyOC5zLUGwJO69VQ>? NYq1Z|U5PzJiaB?= NFHrUWlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1XnZVI3PDF3MkK1
H1299 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXJNE4yNTFyIN88US=> MmTlO|IhcA>? MY\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGXhPGczPjRzNUKyOS=>
A549 NFPQSI9HfW6ldHnvckBCe3OjeR?= NH3U[Y0yNzJwNT:1JO69VQ>? NXXTfZhKOTJiaB?= MWNCpJdm[WuueTDk[YNz\WG|ZXSgRoNtNTJibHX2[Yx{ M1PRV|I3PDF3MkK1
H1299 MoroSpVv[3Srb36gRZN{[Xl? M4nteVEwOi53L{Wg{txO NX;Dc|hMOTJiaB?= MoCzxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? MonuNlY1OTV{MkW=
H157 M4r6cWZ2dmO2aX;uJGF{e2G7 M{XyZlEwOi53L{Wg{txO M1fLdFEzKGh? NXjrRYlT\GWlcnXhd4VlKESUNDDlfJBz\XO|aX;u M4HsWVI3PDF3MkK1
H1299 Mn3DSpVv[3Srb36gRZN{[Xl? MXKxM|IvPS93IN88US=> M1jyc|EzKGh? MkDh[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w M1e1eFI3PDF3MkK1
C8161 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUHUcIxjOC1{IN88US=> MmPkOEBl MX7EUXNQ NITpNFNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{PCRlI3Ozl5MkKz
Mel285 MkG5R4VtdCCYaXHibYxqfHliQYPzZZk> M{HhZVAuOiEQvF2= M1nOblQh\A>? NV24V5d6TE2VTx?= M4X2cIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWGyOlM6PzJ{Mx?=
Mel290 M2XONWNmdGxiVnnhZoltcXS7IFHzd4F6 NHraSoIxNTJizszN NUjsXGRwPCCm MYnEUXNQ Mk\t[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWiyOlM6PzJ{Mx?=
92.1 NInGZ2FE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVTsN|JUOC1{IN88US=> MXm0JIQ> NELxU4dFVVOR MorJ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIOzUZUzPjN7N{KyNy=>
Omm1.3 MVXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2TjbVAuOiEQvF2= NGH1d3o1KGR? M3fMVmROW09? MX\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnvDNlY{QTd{MkO=
Mel202 M3XMNWNmdGxiVnnhZoltcXS7IFHzd4F6 NX34VnFOOC1{IN88US=> MYG0JIQ> NG\R[oVFVVOR MVLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVPFcVFLOjZ|OUeyNlM>
Mel270 MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmjyNE0zKM7:TR?= Mkf1OEBl MUfEUXNQ NF2ySHVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnP4NlY{QTd{MkO=
Omm1 NV\zUlI5S2WubDDWbYFjcWyrdImgRZN{[Xl? MUOwMVIh|ryP NI\0dXk1KGR? MXfEUXNQ M2HJVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUKyOlM6PzJ{Mx?=
92.1 NYfT[2pvSXCxcITvd4l{KEG|c3H5 MWO1NFAhdk1? NVi5TGU4PDhiaB?= M365cGROW09? MVfpcoR2[2W|IHHwc5B1d3Orcx?= NVnWbmtxOjZ|OUeyNlM>
Omm1.3 M4TpcGFxd3C2b4Ppd{BCe3OjeR?= NF2z[4E2ODBibl2= M{H6Z|Q5KGh? M1P4[mROW09? MljPbY5lfWOnczDhdI9xfG:|aYO= Mkn1NlY{QTd{MkO=
92.1 MW\D[YxtKEO7Y3zlJGF{e2G7 NHzJOIU2ODBibl2= NIrNRnMzPC92OD:3NkBp MnvmSG1UVw>? MnrRbY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? M1;0c|I3Ozl5MkKz
Omm1.3 MVfD[YxtKEO7Y3zlJGF{e2G7 NHrST5o2ODBibl2= M{LNOFI1NzR6L{eyJIg> M4W2T2ROW09? Mki4bY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? NWH0VmVDOjZ|OUeyNlM>
A549 NUOzd3Z4TnWwY4Tpc44hSXO|YYm= NIm2[4EyODBxNECwM|ExODBibl2= Mkm1NlQhcA>? NY\ufZJMfXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= NVrBbWhDOjZ{MUKxPVk>
MCF-7 MVfGeY5kfGmxbjDBd5NigQ>? M4P2cVExOC92MECvNVAxOCCwTR?= Mlq5NlQhcA>? NGPOfIt2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz M{HOZ|I3OjF{MUm5
HEK293 NVKyTHdPTnWwY4Tpc44hSXO|YYm= MkH6NVAxNzRyMD:xNFAxKG6P MoHaNlQhcA>? NIXSOmh2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz NWTZ[2RwOjZ{MUKxPVk>
858 MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVGwMVEh|ryP Mm\SOUBl MXPEUXNQ NWLMfGxp\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHPMdIczPjJyNkOzNy=>
DDR2L63V M1;pcWNmdGxiVnnhZoltcXS7IFHzd4F6 NHn1UIkxNTFizszN NVPkWGx1PSCm MmfwSG1UVw>? NITuS4xl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmjwNlYzODZ|M{O=
BE(2)-C M2HrPGNmdGxiVnnhZoltcXS7IFHzd4F6 NGLkeFEyKM7:TR?= M3G2PVEuPCCm MoPw[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NEXMN3gzPjB4N{S2OC=>
IMR-32 M1rP[WNmdGxiVnnhZoltcXS7IFHzd4F6 MYKxJO69VQ>? NYe4WFU5OS12IHS= MVXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MlXUNlYxPjd2NkS=
JF MkLUR4VtdCCYaXHibYxqfHliQYPzZZk> Mlf3NUDPxE1? MVmxMVQh\A>? M4\xO4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 M4TmZlI3ODZ5NE[0
BE(2)-M17 M1\mcWNmdGxiVnnhZoltcXS7IFHzd4F6 MmHZNUDPxE1? NWTkUJd4OS12IHS= MlnJ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> M16xV|I3ODZ5NE[0
SK-N-SH M331W2NmdGxiVnnhZoltcXS7IFHzd4F6 M{jzSFEh|ryP MWmxMVQh\A>? Mmfl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MXOyOlA3PzR4NB?=
SK-N-DZ  MoHoR4VtdCCYaXHibYxqfHliQYPzZZk> MVKxJO69VQ>? M1zPXlEuPCCm MojB[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MYWyOlA3PzR4NB?=
HMC-1.1  MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLsRVM2NTVyMECgcm0> M3fGOFQ5KGh? M3KxeGROW09? NWiwUpdVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF\Fb44zPjB3NUOwNy=>
HMC-1.2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zSb|UuPTByMDDuUS=> Mn\hOFghcA>? MWrEUXNQ M{f0NYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M362N|I3ODV3M{Cz
ROSA KIT WT  NUDn[oM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nzdVUuPTByMDDuUS=> MWq0PEBp MYnEUXNQ MUPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MkjYNlYxPTV|MEO=
ROSA KIT D816V Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jhR|UuPTByMDDuUS=> MVm0PEBp M1PEZmROW09? NH;VTopqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUH2VYIzOjZyNUWzNFM>
HMC-1.1  M4jGTGFxd3C2b4Ppd{BCe3OjeR?= Mn\nNlAxNTVyMECgcm0> M33EbVQ5KGh? NU\5SGlwTE2VTx?= M3n3bIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn;ONlYxPTV|MEO=
HMC-1.2 MXLBdI9xfG:|aYOgRZN{[Xl? NH3XdG4zODBvNUCwNEBvVQ>? NWjRfopMPDhiaB?= M{jPZWROW09? M3zjRolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mlq4NlYxPTV|MEO=
ROSA KIT WT  MlTjRZBweHSxc3nzJGF{e2G7 NYHlfXY3OjByLUWwNFAhdk1? Mn7VOFghcA>? MWnEUXNQ M1z1[olv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmraNlYxPTV|MEO=
ROSA KIT D816V MoCwRZBweHSxc3nzJGF{e2G7 NEL0bIgzODBvNUCwNEBvVQ>? NFrL[IE1QCCq M1i3VmROW09? NVjZOYZQcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIjjdYEzPjB3NUOwNy=>
494H M1HJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnIO5k4OiCq MVPEUXNQ M{DXOmlEPTB;MD6xNlLDuTBwMEC0JO69VQ>? NVTSUoRJOjV7NES1OlY>
493H MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonyO|IhcA>? NGHMVpVFVVOR M{Gx[mlEPTB;MD6wOFfDuTBwMEC5JO69VQ>? MYKyOVk1PDV4Nh?=
716H MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr3O|IhcA>? NUTtfVU1TE2VTx?= MoryTWM2OD1yLkKxNuKyOC5yM{Sg{txO M1rnTVI2QTR2NU[2
148I Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPBVXg4OiCq MkPISG1UVw>? MUXJR|UxRTBwMki0xtExNjB|NTFOwG0> MVWyOVk1PDV4Nh?=
98Sc NVnzZY1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljwO|IhcA>? NUD5VHpHTE2VTx?= MlXZTWM2OD1yLkGxOeKyOC5yMESg{txO M2XTVFI2QTR2NU[2
89R MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TqZlczKGh? NYDRdJBRTE2VTx?= M1jmbGlEPTB;MD6xNlbDuTBwMECzJO69VQ>? M3vJXVI2QTR2NU[2
494L NHz2cZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:xdlczKGh? NGLaXopFVVOR NIXuTZRKSzVyPUCuN|E4yrFyLkCxNkDPxE1? NXHMdXB5OjV7NES1OlY>
493L NH;hc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXmNYU6PzJiaB?= M{DQ[WROW09? NGG2UGRKSzVyPUCuNFUxyrFyLkCxNUDPxE1? M{PtTlI2QTR2NU[2
148L MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O5O|czKGh? MlPRSG1UVw>? M4P0cGlEPTB;MD6xOFbDuTBwMEG3JO69VQ>? NWrLRWZGOjV7NES1OlY>
98L M2nCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPoWXUzPzJiaB?= M4nNV2ROW09? NUCyO3FXUUN3ME2wMlMxQcLzMD6wNlkh|ryP M{[4NlI2QTR2NU[2
OS17 NWnoVoFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDzW|Y4OiCq M1KwNWROW09? MWjJR|UxRTBwMEe5xtExNjByMzFOwG0> MnG3NlU6PDR3Nk[=
OS9 M{nqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrqfXRJPzJiaB?= M13Nb2ROW09? M1X3O2lEPTB;MD60NFbDuTBwMEK4JO69VQ>? Mn7WNlU6PDR3Nk[=
MG63 NHzi[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu3NkBp MX\EUXNQ NXHoNFdNUUN3ME2wMlEyPMLzMD6wNlUh|ryP MW[yOVk1PDV4Nh?=
SAOS2 M{XJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETyR2o4OiCq MYfEUXNQ NEDKW3FKSzVyPUCuNlE4yrFyLkCwN{DPxE1? MY[yOVk1PDV4Nh?=
U2OS NEO3OodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;yPItlPzJiaB?= NXHCXW0xTE2VTx?= NVTlRZdsUUN3ME2wMlE6QMLzMD6wNFgh|ryP M3KyVlI2QTR2NU[2
SJSA-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi3NkBp NV65[2NOTE2VTx?= Mo\zTWM2OD1yLkGwNOKyOC5yMUCg{txO NETtfJEzPTl2NEW2Oi=>
494H NFXLdm5CeG:ydH;zbZMhSXO|YYm= NFn2WHYxNjJ3L{CuOU8yNjBizszN MnTENlQhcA>? NYrhc5Q2TE2VTx?= NYjmTFZGcW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li Mn;mNlU6PDR3Nk[=
148I MUjBdI9xfG:|aYOgRZN{[Xl? MoPNNE4zPS9yLkWvNU4xKM7:TR?= NVLuRZE6OjRiaB?= MlrTSG1UVw>? MULpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NWDHfoY6OjV7NES1OlY>
OS17 M2D3dGFxd3C2b4Ppd{BCe3OjeR?= MY[wMlI2NzBwNT:xMlAh|ryP MXmyOEBp NX;F[pJNTE2VTx?= MY\pcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NXi3VpVYOjV7NES1OlY>
494H NHfrO25CeG:ydH;zbZMhSXO|YYm= NXfGVIRVOeLCid88US=> MXe0PEBp MYfEUXNQ M3X0T4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> MlvKNlU6PDR3Nk[=
148I Ml\BRZBweHSxc3nzJGF{e2G7 M3rnelHjiIoQvF2= NYKxZ5ZZPDhiaB?= M{DzPGROW09? NYPqemx4cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 Mn\FNlU6PDR3Nk[=
OS17 MVPBdI9xfG:|aYOgRZN{[Xl? MX6x5qCK|ryP Mlu5OFghcA>? MX3EUXNQ MkL1bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 Ml;INlU6PDR3Nk[=
MOLM13 MXzBdI9xfG:|aYOgRZN{[Xl? NV2zfHdTOjVyIH7N MYO0PEBp MUDEUXNQ MX7pcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? NVX6WZdGOjVyNUO4NlU>
MV4-11  NXrYb21KSXCxcITvd4l{KEG|c3H5 NEL5PW4zPTBibl2= MX[0PEBp Mnr5SG1UVw>? M3\sUIlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?= M4rOc|I2ODV|OEK1
MOLM13 MojrSpVv[3Srb36gRZN{[Xl? NHTYdoIzPTBibl2= NXTISWZROjRiaB?= NY\NW2pRTE2VTx?= MYflcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB? MXOyOVA2Ozh{NR?=
MV4-11  MWTGeY5kfGmxbjDBd5NigQ>? MmjoNlUxKG6P NEfBdFMzPCCq NEiwO4VFVVOR NUi4Ond{\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ NUDWOpMxOjVyNUO4NlU>
MOLM13 NFTrdpFCeG:ydH;zbZMhSXO|YYm= NGjlW|YzPTBibl2= MnnPOFghcA>? MWLEUXNQ NYr5TZF7cW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?= MmXONlUxPTN6MkW=
MV4-11  MVXBdI9xfG:|aYOgRZN{[Xl? M3;LcFI2OCCwTR?= NXKwd5ZEPDhiaB?= NFzlZYpFVVOR MmPybY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? NFzuSFYzPTB3M{iyOS=>
Hela MmnlR4VtdCCYaXHibYxqfHliQYPzZZk> MlzENE02ODBibl2= NWjjflRxPzJiaB?= MVfEUXNQ NEX5NJll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGLOd2YzPTByOUK5OS=>
HBL-1 NUHBVG5TS2WubDDWbYFjcWyrdImgRZN{[Xl? M3TPUVAuPTByIH7N NEHXOXA4OiCq NGXHcWJFVVOR MnfY[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkD3NlUxODl{OUW=
HLY-1 MmHIR4VtdCCYaXHibYxqfHliQYPzZZk> M4ixXFAuPTByIH7N NH3PNIc4OiCq MonQSG1UVw>? NIToNmdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MoXjNlUxODl{OUW=
OCI-Ly3 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmLhNE02ODBibl2= M17jXFczKGh? MlfLSG1UVw>? MnnG[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmnHNlUxODl{OUW=
OCI-Ly10 NUDjUpNQS2WubDDWbYFjcWyrdImgRZN{[Xl? NUXW[pJlOC13MECgcm0> NVmzbXhoPzJiaB?= NXe5Z3pUTE2VTx?= NVTOeVVz\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MoeyNlUxODl{OUW=
SU-DHL-4 NVTlOlZoS2WubDDWbYFjcWyrdImgRZN{[Xl? Mn:yNE02ODBibl2= M3\qU|czKGh? NEHJeGRFVVOR NFTQOJVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NEThUXkzPTByOUK5OS=>
SU-DHL-5 MonuR4VtdCCYaXHibYxqfHliQYPzZZk> MmDFNE02ODBibl2= MkfhO|IhcA>? NX64c|RpTE2VTx?= MkX2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NH3LS4kzPTByOUK5OS=>
SU-DHL-6 MlL2R4VtdCCYaXHibYxqfHliQYPzZZk> NHW2dHQxNTVyMDDuUS=> M{DLcVczKGh? NID0Z5ZFVVOR NFf0XnRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlnlNlUxODl{OUW=
SU-DHL-10 NUXDeJg3S2WubDDWbYFjcWyrdImgRZN{[Xl? NWPGOHJTOC13MECgcm0> MXi3NkBp NHvifnVFVVOR NVPSOmJT\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVeyOVAxQTJ7NR?=
RC-K8 NXX2VIZ5S2WubDDWbYFjcWyrdImgRZN{[Xl? NUKxZllIOC13MECgcm0> M{L6eVczKGh? M1m5[2ROW09? MWTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXyyOVAxQTJ7NR?=
OCI-Ly8 M33xS2NmdGxiVnnhZoltcXS7IFHzd4F6 NW\KbG9xOC13MECgcm0> MkDNO|IhcA>? NHKxbpJFVVOR M{XJUoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4L6elI2ODB7Mkm1
OCL-Ly18 MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mn7yNE02ODBibl2= MmG2O|IhcA>? MUDEUXNQ Mn\h[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3HySVI2ODB7Mkm1
OCI-Ly3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnTNnUyPzJxMkWwM|UxOCCwTR?= M4K4U|IwPyCm NVm5fm44TE2VTx?= NV63NZZzcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> Mn;ENlUxODl{OUW=
OCI-Ly8 NXT2e21GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj2[|UyPzJxMkWwM|UxOCCwTR?= Mn3CNk84KGR? M{PkVWROW09? M33OOYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= NYfXbIIxOjVyMEmyPVU>
SU-DHL-4 M1nJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonHNVczNzJ3MD:1NFAhdk1? NVjjeHpROi95IHS= NFr5W3ZFVVOR Ml\TbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= MXSyOVAxQTJ7NR?=
SU-DHL-10 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\XNVczNzJ3MD:1NFAhdk1? MXmyM|ch\A>? M4TXRmROW09? Mn3zbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= NYjzcXR1OjVyMEmyPVU>
OCI-Ly3 M3jmW2Fxd3C2b4Ppd{BCe3OjeR?= NYLBUGY4OTd{L{K1NEBvVQ>? Ml7UO4Q> MnnQSG1UVw>? M3Hxdolv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> M1j2[lI2ODB7Mkm1
OCI-Ly8 M1m0VGFxd3C2b4Ppd{BCe3OjeR?= NFHzV2kyPzJxMkWwJI5O M3PZWFdl NYHVdWNTTE2VTx?= M4POUolv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> MWSyOVAxQTJ7NR?=
SU-DHL-4 MXfBdI9xfG:|aYOgRZN{[Xl? MnjrNVczNzJ3MDDuUS=> Ml;GO4Q> MUDEUXNQ NWrtc44ycW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 MWiyOVAxQTJ7NR?=
SU-DHL-10 NGP2XItCeG:ydH;zbZMhSXO|YYm= NHXpXnMyPzJxMkWwJI5O NILqW4k4\A>? MUPEUXNQ NICydpBqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> MW[yOVAxQTJ7NR?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; 

PubMed: 26119999     


The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. 

c-Myc; 

PubMed: 23792448     


PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. 

p27; 

PubMed: 23792448     


Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.

26119999 23792448
Growth inhibition assay
Cell viability; 

PubMed: 23792448     


PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control. 

23792448
Immunofluorescence
GM130; 

PubMed: 29074567     


Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. 

MHC / EdU; 

PubMed: 28733670     


C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.

29074567 28733670
In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]
- Collapse
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]
- Collapse
  • Animal Models: Mice bearing NMC 797 xenografts
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S
CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A
Smiles CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

selleck catalog

Target Protein Ligand Inhibitors with Unique Features

  • Pan BET Inhibitor

    Bromosporine : Pan-BET inhibitor, BRD2, IC50=0.41 μM; BRD4, IC50=0.29 μM; BRD9, IC50=0.122 μM; CECR2, IC50=0.017 μM.

  • BET Inhibitor in Clinical Trial

    RVX-208 New : Phase II for Dyslipidemia.

  • Newest BET Inhibitor

    I-BET-762 : Inhibitor for BET proteins with IC50 of ~35 nM, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.

  • Classic BET Inhibitor

    I-BET151 (GSK1210151A) : Novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively.

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID